UDK 61 Медицина. Охрана здоровья
Therapy with genetically engineered biological drugs is a new approach to the treatment of autoimmune and allergic diseases in pulmonology, hematology, gastroenterology, neurology, and oncology. Today, thanks to them, it is possible to radically improve the quality of life of patients with diseases that were previously considered incurable and poorly controlled. In some cases, the use of therapy can achieve long-term and stable remission. The article provides an overview of genetically engineered biological drugs used in various therapeutic areas and the mechanisms of their action.
genetically engineered biological drugs, bronchial asthma, omalizumab, omalizumab, omalizumab, lebrikizumab, tralokinumab, dupilumab, mepolizumab, benralizumab, fevipiprant.
1. Zyryanov S.K., Butranova O.I. Genno-inzhenerno-biologicheskie preparaty v terapii bronhial'noy astmy: sovremennye dostizheniya. Pul'monologiya. 2018; 28
2. Menzella F., Galeone C., Bertolini F. et al. Innovative treat-ments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017;
3. Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137
4. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107.
5. Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016;
6. Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138
7. Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70
8. Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44
9. Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4
10. Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10
11. Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130
12. Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380
13. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380
14. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371
15. Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11
16. Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12
17. Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016
18. Kang-Moon Lee, Yoon Tae Jeen, Ju Yeon Cho, Chang Kyun Lee, Ja-Seol Koo, Dong Il Park, Jong Pil Im, Soo Jung Park, You Sun Kim, Tae Oh Kim, Suck-Ho Lee, Byung Ik Jang, Ji Won Kim, Young Sook Park, Eun-Soo Kim, Chang Hwan Choi, Hyo Jong Kim. Efficacy, Safety, and Predictors of Response to Infliximab Therapy for Ulcerative Colitis.A Korean Multicenter Retrospective Study.J Gastroenterol Hepatol. 2013;28(12):1829-1833.
19. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. Mucosal Immunology. 2005;30:681-701.
20. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333
21. Harousseau JL. Interet clinique de l'interferon alpha dans le traitement des hemopathies malignes.Presse Med 1997; 26: 857 - 9.
22. Kieseier BC. The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis. CNS Drugs. 2011;25
23. Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F, Cohen JA. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler J. 2014;20
24. Immune system resetting and long-term remission in multiple sclerosis: rationale and possibilities an EXCEMED Satellite Symposium at the 3rd EAN Congress/EXCEMED [Elektronnyy resurs]. Data obrascheniya: 25.12.18. URL: https://www.excemed.org/live-events/immune-systemresetting-and-long-term-remission-multiple-sclerosis-rationale-andpossibilities-excemed-satellite-symposium-3rd-ean-congress
25. Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89 11
26. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2)
27. McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet. 2019;393(10182):1683. https://doi.org/10.1016/S0140-6736(19)30935-3
28. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35. https://doi.org/10.1097/WNF.0b013e318204cd90
29. Salles G. I dr. Rituksimab pri V-kletochnyh gematologicheskih zlokachestvennyh novoobrazovaniyah: obzor 20-letnego klinicheskogo opyta.Adv.2017 PMID 28983798
30. Tarasova L.V., Busalaeva E.I., Cyganova Yu.V., Zhudylina N.V., Matysyakevich I.D. Opyt primeneniya vedolizumaba pri yazvennom kolite (klinicheskiy sluchay). Dokazatel'naya gastroenterologiya. 2020;9(3):77-82. https://doi.org/10.17116/dokgastro2020903177
